Walleye Capital LLC Invests $892,000 in Neuronetics, Inc. $STIM

Key Points

• Walleye Capital LLC purchased a new stake in Neuronetics, acquiring 242,354 shares valued at approximately $892,000, representing about 0.37% of the company.
• Neuronetics reported a quarterly earnings miss, with an earnings per share of ($0.15), falling short of analyst expectations, yet revenue reached $38.11 million, surpassing projections.
• Analysts have a cautious outlook, with Canaccord Genuity reducing its price target for Neuronetics from $8.00 to $7.00 while maintaining a "buy" rating for the stock.

Walleye Capital LLC purchased a new stake in Neuronetics, Inc. (NASDAQ:STIM - Free Report) during the first quarter, according to its most recent filing with the SEC. The fund purchased 242,354 shares of the company's stock, valued at approximately $892,000. Walleye Capital LLC owned about 0.37% of Neuronetics as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of STIM. Larson Financial Group LLC bought a new stake in Neuronetics in the 1st quarter valued at $25,000. KPP Advisory Services LLC bought a new stake in Neuronetics in the 1st quarter valued at $37,000. National Bank of Canada FI increased its holdings in Neuronetics by 19,491.5% in the 1st quarter. National Bank of Canada FI now owns 11,559 shares of the company's stock valued at $42,000 after acquiring an additional 11,500 shares during the last quarter. Presidio Capital Management LLC bought a new stake in Neuronetics in the 1st quarter valued at $44,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in Neuronetics in the 1st quarter valued at $55,000. 53.59% of the stock is currently owned by institutional investors.

Neuronetics Trading Up 2.4%

NASDAQ:STIM traded up $0.08 during mid-day trading on Thursday, hitting $3.35. 1,280,858 shares of the stock traded hands, compared to its average volume of 1,234,412. The company has a quick ratio of 1.84, a current ratio of 2.02 and a debt-to-equity ratio of 1.76. The stock has a market capitalization of $221.50 million, a price-to-earnings ratio of -2.97 and a beta of 1.28. The firm's 50 day moving average is $3.75 and its two-hundred day moving average is $4.01. Neuronetics, Inc. has a 52 week low of $0.52 and a 52 week high of $5.92.

Neuronetics (NASDAQ:STIM - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.07). The company had revenue of $38.11 million during the quarter, compared to the consensus estimate of $36.80 million. Neuronetics had a negative return on equity of 156.36% and a negative net margin of 43.47%. Neuronetics has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities research analysts predict that Neuronetics, Inc. will post -1.13 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group reduced their target price on shares of Neuronetics from $8.00 to $7.00 and set a "buy" rating on the stock in a report on Wednesday, August 6th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, Neuronetics presently has an average rating of "Buy" and an average target price of $7.00.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.